Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
Market Reaction To Bristol-Myers' Mixed Clinical Results: 'A Little Excessive'
Key FDA Events To Watch Out For In August 2017
The Vetr community has upgraded $BMY to 4.5-Stars. (Vetr)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA


Related Articles (BMY)

View Comments and Join the Discussion!